Pfizer intends to sell about 540 million shares in British consumer healthcare company Haleon, a bookrunner said on Monday, ...

Pfizer intends to offload about 540 million shares in the British consumer healthcare company Haleon, a bookrunner said on ...

Pfizer withdrew its pill for sickle cell disease amid heightened European scrutiny, triggered by death rates seen in clinical ...

Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health ...

Pfizer Inc. plans to sell 540 million worth of shares in Haleon Plc, as it pares back its holding in the UK consumer health ...

This week on Pipeline Moves, the Clinical Trials Arena team investigates candidates in oncology, central nervous system and ...

Pfizer Inc. announced a further reduction of its stake in Haleon Plc, offering to sell about a 5.9% stake in the UK consumer ...

In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season ...

Pfizer said it intends to sell around 540 million ordinary shares in British consumer-healthcare business Haleon, or about 5.9% of the company's issued share capital. The pharmaceutical giant said ...

Pfizer Inc. plans to sell 540 million shares in Haleon Plc, as it pares back its holding in the UK consumer health giant.

The withdrawal comes after postmarketing studies showed that the risks of side effects were greater than the benefits.

Goldman Sachs, JP Morgan, Morgan Stanley and UBS are global coordinators on the trade, with Barclays, Bank of America, BNP ...